Related Experiment Video

Updated: May 30, 2026

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B
05:38

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Published on: January 30, 2017

Registration of influenza vaccines for children in Europe

Marta Granström1, Albertha C G Voordouw

  • 1Department of Microbiology, Tumor- and Cellbiology, Karolinska Institutet and Clinical Microbiology, Karolinska University Hospital Solna, Stockholm, Sweden. marta.granstrom@ki.se

Vaccine
|August 9, 2011
PubMed

Insights

Current influenza vaccines for children require efficacy trials, not just serological data. Revised European guidelines aim for better-characterized vaccines addressing pediatric needs.

Area of Science:

  • Vaccinology
  • Pediatric Immunology
  • Regulatory Science

Background:

  • Current EU-licensed trivalent inactivated influenza vaccines (TIV) rely solely on serological data for adults.
  • Existing European Medicines Agency (EMA) guidelines lack specific acceptance criteria for pediatric influenza vaccine development.
  • A Paediatric Committee review highlighted the need for efficacy trials in pediatric investigation plans for new influenza vaccines.

Purpose of the Study:

  • To review the relevance of current serological assays for children.
  • To address methodological variations in neutralization tests for influenza vaccines.
  • To inform revisions of EMA guidelines for influenza vaccine characterization and pediatric needs.

Main Methods:

  • Literature review on influenza vaccines for children.
  • Analysis of serological assay relevance and performance.
  • Discussion of immune correlates and neuraminidase antibody roles.

Main Results:

  • Current serological assays may not be fully relevant for children.
  • Methodological differences in neutralization tests warrant attention.
  • The role of neuraminidase antibodies in protection is increasingly recognized.

Conclusions:

  • New influenza vaccines for children will require efficacy trials.
  • EMA guidelines are being revised to include pediatric considerations and improve vaccine characterization.
  • The updated guidelines aim to ensure influenza vaccines better meet the needs of children.

More Related Videos

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection05:21

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection

Published on: August 14, 2019

Assessing Respiratory Immune Responses to Haemophilus Influenzae06:32

Assessing Respiratory Immune Responses to Haemophilus Influenzae

Published on: June 29, 2021

Related Concept Videos

Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Vaccinations01:51

Vaccinations

Overview
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...